文献速递糖尿病

替尔泊肽治疗肥胖或超重者的12个月真实世界减重效果

Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12‐Month Real‐World Results
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-10-29

本研究评估替尔泊肽在无糖尿病、符合肥胖用药条件的商业保险人群中的真实世界有效性,分为GLP-1 RA初治组(230人)和GLP-1 RA经治组(123人)。两组均持续使用替尔泊肽12个月,初治组平均体重下降19.3%,经治组平均体重下降13.1%。结果与临床试验报告相当,提示在两类人群中均有临床意义的减重效果。

要点

  • GLP-1 RA初治者持续使用替尔泊肽12个月,平均体重下降19.3%。
  • GLP-1 RA经治者同样持续使用12个月,平均体重下降13.1%。
  • 两组基线时超过85%的人至少有一种肥胖相关并发症。

核心结论

  • 持续使用替尔泊肽12个月后,个体获得临床意义的体重下降,结果与临床试验报告相当。

研究设计与样本

  • 本研究为回顾性观察性队列研究,使用Optum去标识化的Market Clarity数据。
  • GLP-1 RA初治组230人,平均年龄49.5岁,72.2%为女性;GLP-1 RA经治组123人,平均年龄48.9岁,81.3%为女性。

主要发现

  • GLP-1 RA初治组在12个月时平均体重下降19.3%。
  • GLP-1 RA经治组在12个月时平均体重下降13.1%。
  • 两组基线时超过85%的个体至少有一种肥胖相关并发症,最常见为血脂异常、高血压和糖尿病前期。

关键数值与推荐

  • 持续使用替尔泊肽定义为坚持用药至少12个月。
  • GLP-1 RA初治定义为索引前12个月内无GLP-1 RA处方。

临床怎么用

  • 替尔泊肽在GLP-1 RA初治和经治的肥胖或超重非糖尿病人群中均显示出临床意义的减重效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Aims This study assessed the real-world effectiveness of tirzepatide in commercially insured individuals without diabetes, eligible for obesity medications (OMs), including glucagon like-peptide-1 receptor agonist (GLP-1 RA)-naïve individuals (i.e., no GLP-1 RA prescription during the 12-month pre-index period) and GLP-1 RA-experienced individuals. Methods This retrospective, observational cohort study used Optum's de-identified Market Clarity Data (Optum Market Clarity). Adults with ≥ 1 prescription claim for tirzepatide between November 2023 and March 2024, with continuous medical/pharmacy enrollment for ≥ 12 months pre-index and post-index and available pre- and post-index data were included. Baseline demographics, clinical characteristics, and treatment effectiveness (change from baseline in weight, body mass index, and cardiometabolic risk factors) were assessed among OM-eligible individuals who were persistent on tirzepatide for ≥ 12 months. Results The GLP-1 RA-naïve and experienced cohorts included 230 individuals (mean age: 49.5 years, 72.2% female) and 123 individuals (mean age: 48.9 years, 81.3% female), respectively, who were persistent on tirzepatide for 12 months with documented pre- and post-index weight measurements. At baseline, more than 85% of individuals in each cohort had ≥ 1 obesity-related complication, most commonly dyslipidemia, hypertension, and prediabetes. At 12 months post-index, the GLP-1 RA-naïve cohort achieved a mean weight reduction of 19.3%, while the GLP-1 RA-experienced cohort achieved a mean weight reduction of 13.1%. Conclusions After 12 months of persistent tirzepatide use, individuals experienced clinically meaningful weight reduction, comparable to outcomes reported in clinical trials. These real-world findings were observed both in GLP-1 RA-naïve and experienced individuals.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Tirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12‐Month Real‐World Results

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。